Introduction

The increasing availability of biosimilar medicinal products has transformed healthcare by expanding patient access to life-saving biological therapies while reducing treatment costs. Biosimilars are highly similar to an already authorized reference biological product, with no clinically meaningful differences in terms of safety, purity, and potency. Despite rigorous regulatory evaluation prior to approval, continuous safety monitoring remains essential throughout a biosimilar’s lifecycle.

Unlike conventional small-molecule medicines, biological products are complex molecules produced through living systems. Their complexity introduces unique pharmacovigilance challenges, particularly regarding product identification and traceability. Accurate traceability is critical for detecting, evaluating, understanding, and preventing adverse reactions associated with specific biological products.

This article explores the importance of pharmacovigilance for biosimilars, the challenges associated with traceability, and the roles and responsibilities of stakeholders in maintaining an effective safety monitoring system.

Understanding Traceability in Biosimilar Pharmacovigilance

Traceability refers to the ability to accurately identify and track a biological medicinal product from manufacturing through distribution and patient use. In pharmacovigilance, traceability ensures that any reported adverse event can be linked to the exact product administered.

For biosimilars, traceability is particularly important because multiple products may share the same International Nonproprietary Name (INN) while being manufactured by different companies. Variations in manufacturing processes, although carefully controlled, may influence product characteristics and potentially affect safety outcomes.

Regulatory authorities therefore require healthcare professionals and Marketing Authorization Holders (MAHs) to record and report key product identifiers, including:

• Brand name
• Manufacturer name
• Batch or lot number
• Dosage form and strength
• Route of administration

Accurate recording of these details allows authorities to identify potential product-specific or batch-specific safety concerns and implement timely risk minimization measures.

Why Traceability Matters for Patient Safety

Effective traceability forms the foundation of biosimilar pharmacovigilance systems. Without precise product identification, safety signals may become difficult to detect, assess, and manage.

Traceability supports patient safety by enabling:

Early Signal Detection

When adverse events are linked to specific biosimilars or manufacturing batches, regulators and MAHs can identify emerging safety trends more rapidly. Early detection facilitates prompt investigation and intervention.

Product-Specific Safety Assessment

Biological products are not identical copies of one another. Comprehensive traceability allows regulators to distinguish whether a safety concern is associated with a particular biosimilar, the reference product, or a specific manufacturing lot.

Efficient Recall Management

In cases involving quality defects or contamination, batch-level traceability enables targeted recalls, minimizing disruption to patients while protecting public health.

Enhanced Benefit-Risk Evaluation

Accurate product information strengthens post-marketing safety analyses, supporting ongoing assessments of the benefit-risk profile throughout the product lifecycle.

Regulatory Expectations for Biosimilar Pharmacovigilance

Global regulatory agencies have established specific requirements to strengthen traceability for biological medicines.

European Union Requirements

The European Medicines Agency (EMA) emphasizes the importance of recording both the brand name and batch number of biological products in adverse event reports. Under Good Pharmacovigilance Practices (GVP), MAHs are expected to maintain systems that facilitate accurate product identification and signal detection.

United States Requirements

The U.S. Food and Drug Administration (FDA) applies robust post-marketing surveillance requirements to biosimilars. Manufacturers are responsible for monitoring safety data, evaluating adverse events, and implementing risk management activities when required.

World Health Organization Recommendations

The World Health Organization (WHO) encourages member states to strengthen biological product traceability through improved adverse event reporting systems and healthcare professional awareness.

Regardless of jurisdiction, the common regulatory objective is ensuring that adverse events can be traced to the correct biological product and manufacturing batch.

Roles and Responsibilities of Key Stakeholders

Successful biosimilar pharmacovigilance depends on collaboration among multiple stakeholders.

Marketing Authorization Holders (MAHs)

MAHs are responsible for maintaining a comprehensive pharmacovigilance system that supports the collection, evaluation, and reporting of safety information.

Key responsibilities include:

• Collecting and processing adverse event reports
• Ensuring accurate product identification in safety cases
• Monitoring safety signals and trends
• Conducting benefit-risk evaluations
• Submitting regulatory reports within required timelines
• Implementing risk minimization measures when necessary
• Training internal teams and partners on traceability requirements

MAHs should actively encourage the collection of brand names and batch numbers during adverse event reporting.

Healthcare Professionals

Healthcare professionals play a critical role in ensuring traceability.

Their responsibilities include:

• Recording product brand names in patient records
• Documenting batch numbers whenever possible
• Reporting adverse reactions promptly
• Providing complete information during safety reporting
• Supporting investigations of suspected adverse events

Accurate documentation at the point of care significantly enhances the quality of pharmacovigilance data.

Pharmacovigilance Professionals

Pharmacovigilance teams are responsible for maintaining high-quality safety databases and ensuring data integrity.

Their activities include:

• Case processing and medical assessment
• Follow-up for missing product information
• Signal detection and risk evaluation
• Aggregate safety reporting
• Regulatory compliance monitoring
• Coordination with healthcare professionals and regulatory authorities

Special attention should be given to obtaining complete traceability information during case follow-up activities.

Regulatory Authorities

Regulators oversee pharmacovigilance systems and ensure compliance with applicable requirements.

Their responsibilities include:

• Monitoring safety trends
• Evaluating emerging safety signals
• Conducting inspections and audits
• Requiring risk minimization measures when appropriate
• Communicating safety information to healthcare professionals and patients

Effective regulatory oversight contributes to maintaining public confidence in biosimilar medicines.

Common Challenges in Biosimilar Traceability

Despite regulatory efforts, several challenges continue to affect biosimilar traceability.

Incomplete Adverse Event Reports

Many reports lack essential product identifiers such as batch numbers or brand names. Missing information can complicate signal detection and causality assessments.

Product Switching

Patients may switch between reference products and biosimilars during treatment. Inadequate documentation of switching history can make attribution of adverse events more difficult.

Healthcare System Variability

Different healthcare systems use varying approaches to product recording and documentation, creating inconsistencies in traceability practices.

Limited Awareness

Some healthcare professionals may underestimate the importance of recording batch numbers and product-specific information during routine clinical practice.

Best Practices to Strengthen Traceability

Organizations can enhance biosimilar pharmacovigilance through several practical measures.

Promote Complete Documentation

Healthcare providers should consistently document brand names and batch numbers in patient records and adverse event reports.

Improve Staff Training

Regular training programs should emphasize the importance of biological product traceability and reporting requirements.

Enhance Digital Systems

Electronic health records and pharmacovigilance databases should be designed to capture critical product identifiers efficiently.

Conduct Follow-Up Activities

Pharmacovigilance teams should actively seek missing traceability information when processing adverse event reports.

Foster Stakeholder Collaboration

Strong communication between MAHs, healthcare professionals, distributors, and regulators supports effective safety monitoring.

The Future of Biosimilar Pharmacovigilance

Advancements in digital health technologies are expected to improve traceability capabilities significantly. Electronic prescribing systems, barcode scanning, serialization technologies, and integrated healthcare databases can facilitate more accurate product identification and reporting.

Additionally, the growing use of real-world evidence and advanced data analytics may strengthen signal detection and provide deeper insights into the long-term safety profiles of biosimilars.

As biosimilar adoption continues to expand globally, robust pharmacovigilance systems and effective traceability practices will remain essential components of patient safety.

Effective traceability relies on robust pharmacovigilance systems, high-quality case processing, and proactive signal management throughout the product lifecycle. Baupharma’s Pharmacovigilance services support Marketing Authorisation Holders through adverse event management, aggregate reporting, signal detection activities, risk management support, and regulatory compliance to help maintain patient safety and meet evolving global requirements.

Key Takeaways

• Biosimilars require rigorous post-marketing pharmacovigilance due to the complexity of biological medicines.
• Traceability is essential for linking adverse events to specific products and manufacturing batches.
• Accurate recording of brand names and batch numbers improves signal detection and safety evaluations.
• MAHs, healthcare professionals, pharmacovigilance teams, and regulators all share responsibility for maintaining effective traceability.
• Incomplete reporting and product switching remain key challenges in biosimilar pharmacovigilance.
• Digital technologies and improved reporting practices are expected to strengthen future traceability systems.
• Effective traceability ultimately supports patient safety and confidence in biosimilar therapies.